News & Media: All

Oct 10, 2016

Dana Goldman Participates in Kaiser Family Foundation Webinar: Rx Drugs and the U.S. Health System – A Conversation about Election-Cycle Proposals for Lowering Costs

On Wednesday, October 5, the Kaiser Family Foundation hosted a live webinar to discuss proposals for controlling prescription drug costs, examine pros and cons of the ideas, and assess the likelihood that the plans will be enacted. Invited panelist Dana Goldman, a PHE co-founder, focused on i ...

Oct 6, 2016

Philipson in Forbes: Why the Drug Industry and Its Critics Are Both Wrong About How R&D Spending Affects Pricing

In Tomas Philipson' latest commentary, he explains why the drug industry and their critics are both wrong about how R&D spending affects pricing.

To read the complete editorial, please click here.

Sep 27, 2016

New Q&A with Amitabh Chandra in STAT News

Precision Health Economics' Scientific Advisor Amitabh Chandra is interviewed on the subject of precision medicine pricing, in a new Q&A for STAT News.

To read the complete article, please click here.

Sep 20, 2016

Tomas Philipson Addresses UN's Access to Medicines Panel in WSJ Op-Ed

In Tomas Philipson's op-ed for the Wall Street Journal, he addresses the UN's Access to Medicines panel findings, pointing out that restricting the patent system will make it harder, not easier, for the global poor to get medicines.

To read his complete commentary, please click here.

Sep 19, 2016

Precision to Have Strong Presence at ISPOR Europe, October 29th to November 2nd, 2016

At ISPOR's 19th Annual European Congress, to be held from October 29th - November 2nd, 2016 in Vienna, Austria, Precision will have a very strong presence.

Come visit the Precision team in Booths 1000/900/1001/901!

In addition, please look for examples of our expertise in the following sessio ...

Sep 15, 2016

Goldman, Nussbaum and Linthicum in Health Affairs: Innovation Needed in Pricing and Value Measurement

In their new Health Affairs blog post, Dana Goldman, Sam Nussbaum and Mark Linthicum make the case for advancing pricing and value measurement innovation via the launch of the Innovation and Value Initiative (IVI).

To read the complete blog post, please click here.

Sep 13, 2016

Philipson Participates in AEI Panel Debating Price of Specialty Drugs

On Monday, September 12th, 2016 at AEI, health policy experts representing practitioners and industry discussed the issue of high drug prices.

On the panel, Precision's Tomas Philipson cast doubt on the claim that research and development determine pricing, arguing that in reality causality run ...

Sep 6, 2016

Philipson in Forbes: EU vs. US Cancer Care- You Get What You Pay For

In Tomas Philipson's latest Opinion for, he examines cancer care in the EU vs. the US, pointing out some dramatic differences in determining cost-effectiveness.

To read the complete commentary, please click here.

Sep, 2016

PHE's Jason Shafrin Analyzes Value Frameworks for Pharmaceutical Commerce

Precision Health Economics' Senior Research Economist Jason Shafrin provides an in-depth analysis of value frameworks in his new article for Pharmaceutical Commerce: "Value frameworks are here: What to do about them?"

To read the complete article, please click here.

Aug 26, 2016

Precision's Goldman Addresses the EpiPen Controversy in STAT News

Precision Health Economics' Dana Goldman addresses the firestorm created by Mylan's dramatic price hikes for their EpiPen in a new commentary published in STAT News: "To Prevent Another EpiPen Controversy, the Government Should Step In."

To read the complete commentary, please click here.

Aug 22, 2016

Dana Goldman in the New York Times: Concierge Care Can Help Indigent Uninsured

In Dana Goldman's latest opinion piece for the New York Times, "Hospital Care for Those Who Can Afford It Helps Care for Those Who Can't," he examines the paradox of concierge care and how it may effect those without insurance.

To read the complete editorial, please click here.

Aug 17, 2016

Anupam Jena in The Guardian: Australia's New Drug Guidelines Put Cost-Cutting Before Patients

Precision Health Economics' Principal Scientific Advisor Anupam B. Jena discusses Australia's proposed new guidelines for the PBS (Pharmaceutical Benefit Scheme) in a new commentary for The Guardian.

To read the complete commentary, please click here.

Aug 4, 2016

Tomas Philipson in Forbes: Are You Just a Number?

In Tomas Phillipson's latest commentary (with Precision co-author Jason Shafrin), the development of new value framework criteria and it's impact on both patients and physicians are examined.

To read the complete commentary, please click here.

Jul 14, 2016

Philipson in Forbes: "If It Ain't Broke, Don't Fix It"

In Tomas Philipson's latest Op-Ed for, he addresses pharmaceutical innovation and the recent open letter by the UAEM: "If It Ain't Broke, Don't Fix It."

To read the complete commentary, please click here.

Jul 11, 2016

Precision's Chung, MacEwan and Goldman in Health Affairs: "One Size Fits All?"

Precision's Adrienne Chung, Joanna MacEwan, and Dana Goldman address formulary policy in a new Health Affairs blog: "Does A ‘One-Size-Fits-All’ Formulary Policy Make Sense?"

To read the complete commentary, please click here.

Jul 7, 2016

Precision's Darius Lakdawalla in the AP: A Model for More Rational Drug Prices

Precision's Darius Lakdawalla is featured in The AP's Big Story, discussing the need for a more rational drug pricing model.

To read the complete story, please click here.

Jun 30, 2016

Goldman in Modern Healthcare: Take A Lesson From Vaccines

PHE's Dana Goldman, in his latest commentary for Modern Healthcare, suggests that improving access and pricing for generic drugs could be accomplished by taking a lesson from vaccine policy.

To read the complete article, please click here.

Jun 3, 2016

Philipson in Forbes: Give Tax Payers A Rebate for Medical Innovation?

In Tomas Philipson's latest commentary, he examines tax-funded R&D medical spending and the market value of that research.

Read the article here.

Jun, 2016

Precision's Renick In The Pink Sheet: Importance of Data

Will data be enough to support a new drug that battles COPD?  In a recent article in The Pink Sheet, Precision’s Dan Renick weighs in on the importance of data to understand the potential impact:

The Pink Sheet

May 30, 2016

Real World Superiority Data May Not Be Enough To Boost GSK's Breo I ...

Jun, 2016

Renick in The Pink Sheet: Showing Value at Launch for Competing Drugs

Precision’s Dan Renick comments in The Pink Sheet on the importance of showing value when there are competing drugs at the time of launch:

The Pink Sheet

May 30, 2016

GSK Leads Way With Real World Data, But Others Follow

By Emily Hayes


Executive S ...

Jun, 2016

Lakdawalla in AP's The Big Story: "Why Aren't You Shopping for Lower Prescription Drug Prices?"

Precision Health Economics founder and Chief Strategy Officer Darius Lakdawalla discusses the concept of shopping for the lowest prescription drug prices and "pharmacy apps" with Matthew Perrone of AP's The Big Story.

To read the article, please click here

May 31, 2016

PHE’s Goldman, Lakdawalla, and Philipson To Participate in BIO Panel

Precision Health Economics’ (PHE) Dana Goldman, Darius Lakdawalla, and Tomas Philipson will be featured in the BIO International Convention panel - The Future of Biosimilars: How Will Policy and Market Dynamics Impact Patient Value and Access in the US?

This panel will take place from 10:45a ...